Startup profile · funding coverage
GC Therapeutics funding, valuation and investors
Cell-therapy biotech using George Church–originated iPSC programming platform TFome.
Verified company research · funding, investors and latest developments
Keep track of GC Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$65M · 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$65M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Cambridge, Massachusetts
Overview
GC Therapeutics (GCTx) develops off-the-shelf cell therapies using TFome, a proprietary iPSC programming platform originated from George Church's lab — aiming to manufacture consistent cell products at scale.
Why GC Therapeutics is interesting
GC Therapeutics targets scalable off-the-shelf cell therapies; a16z Bio + Health joined Pear VC in its $65M Series A launch round.
Product & use cases
GC Therapeutics (GCTx) uses TFome, an iPSC programming platform from George Church's lab, to manufacture off-the-shelf cell therapies at scale.
- Off-the-shelf regenerative cell products
- Consistent iPSC-derived therapies vs. autologous manufacturing
- Platform licensing for cell therapy developers
Key facts
- Series A (2024): $65M led by Cormorant Asset Management with a16z Bio + Health (/fund/andreessen-horowitz) and Pear VC (/fund/pear-vc) (BusinessWire)
- TFome platform originated from George Church's lab at Harvard; targets scalable off-the-shelf iPSC cell therapies
Funding history (newest first)
Series A
2024 $65M- Cormorant Asset Management (lead)
- Andreessen Horowitz (participant)
- Pear VC (participant)
Source: Read source · businesswire.com
Investors in our directory
Funds linked from GC Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: TFome platform originated in George Church's Harvard lab — targets manufacturing consistency that autologous cell therapy lacks.
Off-the-shelf cell therapy is a crowded thesis; GCTx bets TFome programming from Church lab IP delivers repeatable products. Clinical validation still ahead.
-
Fate Therapeutics direct
iPSC-derived cell therapies; GCTx differentiates on TFome programming.
-
Century Therapeutics direct
iPSC NK/T cell programs; overlapping off-the-shelf thesis.
-
Autologous CAR-T makers alternative
Patient-specific manufacturing; higher cost, harder scale.
Notable stories
- TFome platform originated from George Church's lab at Harvard (BusinessWire, 2024).
- Launched with $65M Series A to advance off-the-shelf iPSC cell therapies.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about GC Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.